Genome-Wide CRISPR Screens Identify PARP Inhibitor Response in Prostate Cancer
A new study informed use of PARP inhibitors beyond BRCA1/2-deficient tumors and reevaluated biomarkers for PARP inhibition in prostate cancer.
A new study informed use of PARP inhibitors beyond BRCA1/2-deficient tumors and reevaluated biomarkers for PARP inhibition in prostate cancer.
The Crescendo cDNA Synthesis for qPCR system can generate large quantities of cDNA from as little as 500 pg of total RNA.